dp1

Treprostinil (Orenitram) is a potent DP1, IP and EP2 agonist (EC50: 0.6 1.9 6.2 nM).

Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6 1.9 6.2 nM).

Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively. Treprostinil diethanolamine contributes to the upregulation of cAMP, maintaining vascular homeostasis and causing vasodilation in human pulmonary arteries.

TDP1 Inhibitor-1 is a potent inhibitor of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) with an IC50 of 7 μM.

Fructo-oligosaccharide DP11/GF10 is a fructooligosaccharide (FOS) compound with a degree of polymerization (DP) equal to 11. FOS consists of 10 fructose units connected by (2→1)-β-glycosidic bonds, with a single D-glucosyl unit present at the non-reducing end.

Fructo-oligosaccharide DP12 GF11 is a member of fructooligosaccharides (FOS) characterized by a degree of polymerization (DP) of 12. FOS compounds consist of 11 fructose units connected by (2→1)-β-glycosidic bonds, with a lone D-glucosyl unit located at the non-reducing end.

TDP1 Inhibitor-2 is a potent inhibitor of TDP1 (tyrosyl-DNA phosphodiesterase 1) (IC50: 99 nM) and inhibits SCAN1 (spinal cerebellar ataxia syndrome with axonal neuropathy) (IC50: 3.5 μM).

MDP1, derived from Melittin, disrupts the membrane integrity of both Gram-positive and Gram-negative bacteria, leading to bacterial death through membrane damage. This compound exhibits potent antibacterial activity against multidrug-resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa [1].

MDP1 acetate, a derivative of Melittin, compromises the membrane integrity of both Gram-positive and Gram-negative bacteria leading to bacterial death through membrane damage. It exhibits potent antibacterial activity against multidrug-resistant (MDR) and reference strains of S. aureus, E. coli, and P. aeruginosa [1].

SDP116, a synthetic peptide derivative of the GPR116 Stachel sequence, exhibits ADGRF5 agonistic activity [1].

Fructo-oligosaccharide DP14, an oligosaccharide derived from Atractylodes lancea [1], represents a specific polysaccharide subclass with a degree of polymerization of 14.

Fructo-oligosaccharide DP13 is an inulin-type fructan that can be isolated from Morinda officinalis [1].

Fructo-oligosaccharide DP10 GF9 is a compound classified as a fructooligosaccharide (FOS) with a degree of polymerization (DP) of 10. FOS consists of a chain of 9 fructose units connected by (2→1)-β-glycosidic bonds, with a lone D-glucosyl unit located at the non-reducing end.

DP-1, a Ganetespib degradation product, represents a fragment derived from SDC-TRAP-0063. Ganetespib itself functions as an inhibitor of heat shock protein 90 (HSP90), exhibiting notable anti-tumor properties.

DP-1 hydrochloride is a degradation product of SDC-TRAP-0063, a fragment of Ganetespib, a heat shock protein 90 (HSP90) inhibitor with antitumor activity.

Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

PF-04418948 is a potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 μM. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM).

CRTH2-IN-1 is a selective prostaglandin D2 receptor DP2 (CRTH2) antagonist, a Ramatroban analog, with an IC50 of 6 nM in the human DP2 binding assay.

BW 245C is a selective prostaglandin-like DP receptor (DP1) agonist, a prostaglandin analogue with inhibitory effects on the aggregation response of collagen, which can be used to study diseases such as stroke.

Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

S-5751, a prostanoid DP (DP1) antagonist, is used potentially for the treatment of bronchial asthma.

Setipiprant (ACT-129968) is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2, a G protein-coupled receptor for prostaglandin (PGD2), mediates key inflammatory responses related to allergy and asthma. PGD2, produced by mast cells, binds to CRTH2 on blood-borne cells, inducing chemotaxis of Th2 cells, basophils, and eosinophils, and stimulating cytokine release.